{
    "clinical_study": {
        "@rank": "31671", 
        "arm_group": {
            "arm_group_label": "MY-REPT capsule", 
            "arm_group_type": "Experimental", 
            "description": "MY-REPT capsule: Mycophenolate mofetil, 250mg/cap, orally"
        }, 
        "brief_summary": {
            "textblock": "Efficacy and safety of MY-REPT capsule in primary, liver transplantation recipients"
        }, 
        "brief_title": "The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Evidence of Liver Transplantation", 
        "detailed_description": {
            "textblock": "Open label, Multicenter, Non-comparative Study to evaluate the efficacy and safety of\n      MY-REPT capsule in primary, liver transplantation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with primary liver transplantation recipients\n\n          -  Male and Female aged \u226519 and \u226465\n\n          -  Patient with ABO blood type correspond with Donor's blood type\n\n          -  Patient who agreement with written informed consent\n\n          -  Patient who Women if had childbearing potential must have a negative serum or urine\n             pregnancy test at the screening visit and agreement with contraception\n\n        Exclusion Criteria:\n\n          -  Patient with secondary liver transplantation(LT) recipient or other organ\n             transplantation recipient in past or current\n\n          -  Patient with multi-organ transplantation recipient\n\n          -  Patient with dual-graft transplantation recipient\n\n          -  Patient who used body artificial liver before LT\n\n          -  Cr level >2.0mg/dL in screening\n\n          -  WBC <2,000/mm3 or ANC <900/mm3 or PLT <30,000/mm3 in screening\n\n          -  Patient who experienced severe gastrointestinal disorder so investigator judge the\n             man's participation impossible\n\n          -  Patient who experienced severe infection (need to treatment)\n\n          -  Patient or Donor with HIV positive\n\n          -  Patient who need to treat with immunosuppressant or chemistry therapy\n\n          -  Patient who had taken immunosuppressant within 30days before LT (except to take\n             Corticosteroids and Tacrolimus due to protocol)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01766518", 
            "org_study_id": "m307LTP09D"
        }, 
        "intervention": {
            "arm_group_label": "MY-REPT capsule", 
            "description": "MY-REPT capsule 500~1500mg/day, per oral, capsules twice a day with Tacrolimus, Corticosteroids, Basiliximab post liver transplantation", 
            "intervention_name": "Mycophenolate mofetil", 
            "intervention_type": "Drug", 
            "other_name": "MY-REPT capsule"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Mycophenolate mofetil", 
                "Mycophenolic Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "liver transplantation", 
            "LT", 
            "Mycophenolate mofetil", 
            "MMF"
        ], 
        "lastchanged_date": "November 6, 2013", 
        "location": [
            {
                "contact": {
                    "email": "sglee2@amc.ac.kr", 
                    "last_name": "SungGyu Lee, Ph.D", 
                    "phone": "+82 2 3010 7182"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Asan medical center"
                }, 
                "investigator": {
                    "last_name": "SungGyu Lee, Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Samsung Medical Center"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul ST Mary's Hospital"
                }, 
                "status": "Completed"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open Label, Multicenter, Non-comparative Study to Evaluate the Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients.", 
        "other_outcome": [
            {
                "measure": "Rate of adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "up to 26 weeks"
            }, 
            {
                "measure": "Laboratory test", 
                "safety_issue": "Yes", 
                "time_frame": "up to 26weeks"
            }, 
            {
                "measure": "Physical exam, pulse rate et.", 
                "safety_issue": "Yes", 
                "time_frame": "up to 26weeks"
            }
        ], 
        "overall_contact": {
            "email": "sglee2@amc.seoul.kr", 
            "last_name": "SungGyu Lee, Ph.D", 
            "phone": "+82 2 3010 7182"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "SungGyu Lee, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Rate acute rejection by liver biopsy", 
            "measure": "Rate of acute rejection", 
            "safety_issue": "No", 
            "time_frame": "up to 26weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01766518"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Frequency, Time, Severity of acute rejection", 
                "safety_issue": "No", 
                "time_frame": "up to 26 weeks"
            }, 
            {
                "measure": "Graft loss, Patient survival rate", 
                "safety_issue": "No", 
                "time_frame": "up to 26weeks"
            }, 
            {
                "measure": "Kidney function test by e-GFR(Glomerular filtration rate)", 
                "safety_issue": "No", 
                "time_frame": "up to 26weeks"
            }, 
            {
                "measure": "Questionnaire of gastrointestinal symptom assessment", 
                "safety_issue": "No", 
                "time_frame": "screening visit, closing visit"
            }, 
            {
                "measure": "Questionnaire of gastrointestinal quality of life index", 
                "safety_issue": "No", 
                "time_frame": "screening visit, closing visit"
            }
        ], 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2009", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}